Laurie Withington
Principal Analyst
USA
14+ years of experience
Laurie maintains and updates the products she works on, mainly Trialtrove and Analytics, and provides insight
and analysis in blogs and whitepapers on various diseases.
She initially worked in the Trialscape group when she joined Informa in 2008, providing custom analytics
projects to clients. Following this, she worked in the Trialtrove group in oncology, as well as in CNS,
autoimmune, and ophthalmology.
Before joining Informa, Laurie was a Cardiovascular/Metabolic Disease Portfolio Manager at Wyeth Pharma,
where she managed the risk, potential success, and logistics of the drugs in pipeline leading up to Phase I.
Trialtrove
By Laurie Withington 09 May 2018
The wearable technology market is rapidly growing, and impacting many different areas of our culture such as social interaction, entertainment, environment, self-awareness, and healthcare. Techcrunch has forecasted sales of wearable devices worldwide this year at $30.5BN in total revenue . As more money is spent on wearable devices, innovation expands, which in turn increases the many facets of our lives that these devices can be incorporated into.
Topic Clinical Trials
Trialtrove
By Laurie Withington 20 Dec 2017
There have been numerous failures of Alzheimer’s dementia drugs in the past five years.
Topic Alzheimer's Disease
Laurie Withington 10 Mar 2015
Two new diseases were recently added to Trialtrove, retinitis pigmentosa and spinal muscular atrophy.
Laurie Withington 01 May 2014
A report that analyses the current clinical development landscape for Parkinson's Disease